Business Expansions, New Contracts, Product Launches, and Regulatory Approvals - Research Report on Alexion, Actavis,

Business Expansions, New Contracts, Product Launches, and Regulatory Approvals
   - Research Report on Alexion, Actavis, CombiMatrix, Globus Medical, and

PR Newswire

NEW YORK, June 28, 2013

NEW YORK, June 28, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Alexion
Pharmaceuticals, Inc. (NASDAQ: ALXN), Actavis Inc. (NYSE: ACT), CombiMatrix
Corporation (NASDAQ: CBMX), Globus Medical Inc. (NYSE: GMED), and Teleflex
Incorporated (NYSE: TFX). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Alexion Pharmaceuticals, Inc. Research Report

On June 17, 2013, Alexion Pharmaceuticals Inc. (Alexion) reported that it was
joined by state and local officials in a ceremony for 100 College Street, a
laboratory office building that will house the Company's new global
headquarters in New Haven, Connecticut. According to Alexion, the event marked
a milestone in the expansion of its research and business operations as it
continues to develop a broad portfolio of life-transforming therapies for
patients. Leonard Bell, MD, Chief Executive Officer of Alexion, said, "Our new
global headquarters will support our continued growth as we work to develop
and deliver life-transforming therapies for patients with severe and
life-threatening disorders that are also ultra-rare." Alexion reported that it
will be the anchor tenant in 100 College Street, occupying nine floors, and
expects the building to be open for occupancy in 2015. The Full Research
Report on Alexion Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: []

Actavis Inc. Research Report

On June 25, 2013, Actavis Inc. (Actavis) announced that Health Canada has
approved the Company's application to market FIBRISTAL (ulipristal acetate)
for the treatment of moderate to severe signs and symptoms of uterine fibroids
in adult women of reproductive age, who are eligible for surgery. Expected to
be available in Canada in Q3 2013, Actavis claims that FIBRISTAL is a
breakthrough first-in-class oral treatment that offers an important new option
for women in Canada with uterine fibroids, being the first approved medication
to reduce fibroid size as well as control symptoms. Current treatments for
uterine fibroids include off-label medication to reduce symptoms, or surgery
to remove fibroids if they become severe. The Company stated that two
double-blind, controlled, multicenter, Phase 3 studies showed that FIBRISTAL
significantly reduced heavy bleeding during menstruation, pain and discomfort
and the overall volume of fibroids. Besides, the Company claims that a three
month treatment with FIBRISTAL helps to maintain the reduced size of fibroid
for at least six months. The Full Research Report on Actavis Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

CombiMatrix Corporation Research Report

On June 25, 2013, CombiMatrix Corporation (CombiMatrix) announced that its
chromosomal microarray analysis (CMA) test for miscarriage analysis has
received conditional approval from the New York State's Department of Health
for testing on patient samples from the state. The CMA test for miscarriage
analysis, also called Product of Conception test, is currently the Company's
fastest growing test in terms of volumes. On June 18, 2013, the Company had
announced that volumes from both of its prenatal CMA tests have increased
significantly in the past six months following the publication of data from
two National Institutes of Health (NIH) studies that indicated the superiority
of CMA over traditional karyotyping for identifying clinically significant
genetic abnormalities. Mark McDonough, CEO of CombiMatrix, said, "As approved
under the conditional license, we will now begin to sell directly to customers
and to seek distribution partnerships to leverage our internal sales force."
The Full Research Report on CombiMatrix Corporation - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: []

Globus Medical Inc. Research Report

On June 20, 2013, Globus Medical Inc. (Globus) announced the launch of LATIS,
a minimally invasive (MIS) lumbar interbody fusion spacer for patients
suffering from degenerative disc disease (DDD). According to the Company, the
implant may be inserted through an MIS transforaminal lumbar interbody fusion
(TLIF) approach and expands laterally to provide a footprint and graft volume
equivalent to an anterior lumbar interbody fusion (ALIF) spacer or lateral
lumbar interbody fusion (LLIF) spacer. Andrew Iott, Senior Vice President,
Global Product Development of Globus, said, "This new addition to our MIS
portfolio is the first expandable implant on the market to offer the benefits
of a traditional anterior implant, without the two-part disruptive surgical
procedure. Combined with posterior stabilization using our REVOLVE MIS pedicle
screw system, the entire procedure is designed and intended to maximize
preservation of the stabilizing muscles of the lower back." Full Research
Report on Globus Medical Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

Teleflex Incorporated Research Report

On June 25, 2013, Teleflex Incorporated (Teleflex) announced that it has
signed a new agreement with HealthTrust for its complete line of LMA Laryngeal
Masks. Under the term of the agreement, Teleflex will provide HealthTrust's
1,400 member hospital access to its comprehensive portfolio of laryngeal
masks, with effect from July 1, 2013.. The Company informed that the full
offering provides airway management products including LMA Supreme Laryngeal
Mask, the LMA Classic Airway, the LMA Unique Airway, and the LMA ProSeal
Airway. Cary Vance, President, Anesthesia & Respiratory Division of Teleflex,
said, "This new agreement with HealthTrust further strengthens Teleflex's
position as a market leader in laryngeal masks in the United States." The Full
Research Report on Teleflex Incorporated - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: []


1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: Media Contact:, Phone #: +1-310-496-8071 (North
Press spacebar to pause and continue. Press esc to stop.